Chinese guideline for the diagnosis and management of CADASIL (2022 edition): a protocol

Abstract

In order to promote the clinical diagnosis, management and treatment of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) in China, it is necessary to construct evidence ⁃ based guidelines. The "Chinese guideline for the diagnosis and management of CADASIL (2022 edition)" will be written by using the World Health Organization (WHO) Guidelines Development Manual" and "Principles for Developing/Revising Clinical Diagnosis and Treatment Guidelines in China (2022 Edition)", and follow the evidence ⁃ based guidance development process to develop and publish formal guidance. This guide plan mainly describes the background, initiation and planning of the guide, as well as a concise development method to lay the foundation for the successful release of the subsequent guide.

DOI: 10.3969/j.issn.1672⁃6731.2023.11.002